• Download mobile app
22 Jan 2021, Edition - 2019, Friday

Trending Now

  • Delhi Police to decide on farmers’ entry into capital, SC says
  • Will incorporate ‘Karnataka-occupied areas’ in Maharashtra: CM Uddhav Thackeray
  • Indian players have been tested to the cricketing and mental limits every turn, every minute: Gavaskar

Businesswire

Taro Terminates Agreement with NovaBiotics

by businesswireindia.com

Share
Business Wire India

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) announced today that it has terminated the license agreement with NovaBiotics for the onychomycosis drug, Novexatin®.

 

As previously disclosed in May 2018, the Novexatin® clinical study did not meet the main goal of a Phase IIb study under current guidelines of the FDA and did not show superiority over the placebo. Upon further analysis and evaluation, the Company has decided to terminate its agreement with NovaBiotics.

 

About Taro

 

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

 

About NovaBiotics

 

NovaBiotics Ltd is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.

 

 
Source: Businesswire
COIMBATORE WEATHER